Perrigo (PRGO) Share-based Compensation (2013 - 2026)
Perrigo's (PRGO) quarterly Share-based Compensation came in at $14.4 million in Q1 2026, up 21.01% year-on-year from $11.9 million in Q1 2025, and up 4700.0% on a QoQ basis from $300000.0 in Q4 2025.
Perrigo (PRGO) Share-based Compensation (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Share-based Compensation data on file, last reported at $14.4 million in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 21.01% year-over-year to $14.4 million in Q1 2026; TTM through Mar 2026 was $21.6 million, a 83.05% increase from a year earlier, with the FY2025 full-year figure at $19.1 million, up 23.23% from the prior year.
- Share-based Compensation for Q1 2026 stood at $14.4 million, up from $300000.0 in the prior quarter.
- Over the last five years, Share-based Compensation for PRGO reached as high as $26.3 million in Q2 2022 and fell as low as -$23.6 million in Q3 2024.
- Historically, Share-based Compensation has averaged $10.2 million across 5 years, with a median of $11.9 million in 2025.
- Across the five-year window, Share-based Compensation jumped 69.09% in 2023 and tumbled 260.54% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $8.2 million in 2022, then grew by 29.27% to $10.6 million in 2023, then sank by 95.28% to $500000.0 in 2024, then sank by 40.0% to $300000.0 in 2025, then surged by 4700.0% to $14.4 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $14.4 million in Q1 2026, $300000.0 in Q4 2025, and -$9.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 14.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 14.40 Mn |
| Mar 28, 2026 | 14.40 Mn |
| Dec 31, 2025 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Sep 27, 2025 | -9.60 Mn |
| Sep 27, 2025 | -9.60 Mn |
| Jun 28, 2025 | 16.50 Mn |
| Jun 28, 2025 | 16.50 Mn |
| Mar 29, 2025 | 11.90 Mn |
| Mar 29, 2025 | 11.90 Mn |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 28, 2024 | -23.60 Mn |
| Sep 28, 2024 | -23.60 Mn |
| Jun 29, 2024 | 23.00 Mn |
| Jun 29, 2024 | 23.00 Mn |
| Mar 30, 2024 | 15.60 Mn |
| Mar 30, 2024 | 15.60 Mn |
| Dec 31, 2023 | 10.60 Mn |
| Dec 31, 2023 | 10.60 Mn |